Hadasit Bio-Holdings Ltd. (Logo)
HBL –Hadasit Bio-Holdings Ltd.
May 1st, 2015
Israel Securities Authority Tel Aviv Stock Exchange Ltd.
Re: The Results of Protab Ltd.’s Pre-Clinical Trials
Following the disclosure provided by the Company as part of Section 30.1.10 of Chapter 1 of the Company’s Periodic Report for 2014, as published on March 23, 2015 (Reference No.: 2015-01-058795), regarding pre-clinical trials by Protab Ltd., a subsidiary in which the Company holds 69.54% (hereinafter: “Protab”), on animal models to test the antibody Prozomab’s effectiveness for new clinical indications, some for the development of an orphan drug (Orphan Drug Indication), and some in which there is a real need for new drugs (Unmet Clinical Need), (hereinafter: “the preclinical trials”), the company hereby announces as follows:
On April 30th, 2015, Protab notified the Company that it had concluded its analysis of the results of the preclinical trials that had as a goal to reach results allowing for a decision to be made regarding a focus on the leading indication for Prozomab’s clinical development.
From the analysis of the preclinical trials’ results from models for new indications, including the trials in Behcet disease models carried out at the National Institute of Health in the United States, the NIH, it is suggested that there are no significant results that support the development of Prozomab for these indications.
In accordance with the above, Protab will continue to work to develop Prozomab for inflammatory bowel diseases (including Crohn’s and ulcerative colitis), as well as for other auto-immune diseases, and plans on raising capital for further development.
HBL – Hadasit Bio-Holdings Ltd.
By: Ms. Tamar Kfir, CEO